What the research found
Market analysts cited a Citigroup survey suggesting roughly 28% of US adults use peptides and spend an average of $90 monthly, which when extrapolated yields an estimated $80 billion annual market opportunity. The arithmetic itself is straightforward: 28% of ~260 million adults equals ~73 million people; at $90/month for twelve months, that totals approximately $78–80 billion.
However, the source material underlying this figure remains inaccessible—the original Financial Times column and Citigroup data were behind paywalls, and no details are publicly available about the survey's methodology, exact wording, sample size, or how respondents were recruited. This matters because the same headline number can be derived from very different customer behaviours: the estimate assumes each person pays for 12 months annually, but the survey question may have simply asked whether someone has "ever tried" a peptide, which would include people who experimented once, stopped, or use intermittently.
Why it matters for you
The $80 billion figure floats through media and investor conversations as though it describes current sales, but it's a potential market size based on stated spending intentions—not money already changing hands. If you're considering peptide protocols or comparing them to other performance interventions, this distinction is worth holding: survey willingness and actual sustained spending are different things. The gap between "I'd spend $90/month on this" and "I actually did, every month for a year" is where real market uncertainty lives.
More practically, this ambiguity also highlights why tracking your own biomarkers and responses matters more than aggregate estimates. Whether peptides work for you—measured against your own blood work, recovery, injury healing or other tracked outcomes—is independent of whether millions of other people claim to use them. Market size tells you nothing about efficacy or whether a given protocol fits your training age, goals or health profile.
Caveats
- Survey methodology not disclosed: The original questionnaire wording, sample design, recruitment method and sample size are unavailable for independent review.
- "Ever used" vs. "paid annually" ambiguity: The 28% figure may capture people who tried peptides once, not people who maintain monthly spending year-round; no data on average customer tenure or dropout rates.
- Extrapolation arithmetic, not market data: The $80 billion is a mathematical projection from stated intentions, not observed sales or revenue figures.
- Representativeness unknown: No information on whether the survey sample was representative of the US adult population or skewed toward younger, wealthier or more health-engaged groups.
- Missing price context: The $90/month average does not specify whether it assumes prescription access, clinical evidence, insurance coverage or unregulated compounded products.